Clinical Trials Directory

Trials / Terminated

TerminatedNCT02365909

Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)

A Prospective Randomized Double-Blind Placebo Controlled Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)

Status
Terminated
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
6 (actual)
Sponsor
University of Arkansas · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Postdural puncture headaches (PDPH) are a consequence of spinal and epidural anesthesia in approximately 1% of cases when performed in obstetric patients. The gold standard treatment for a PDPH is currently an epidural blood patch (EBP), which involves placing a needle back into the epidural space of the neuraxium and then injecting 20 ml of the patient's own blood through the needle and into the epidural space to form a clot over the insult in the tissue layer that causes the headaches. The investigators want to test the efficacy of using a less invasive procedure, called a sphenopalatine block (SPGB), for treatment of PDPH. SPGB has been used for many years in the treatment of migraines and cluster headaches, and there are several case reports of its use to successfully treat PDPH as well. SPGB simply involves applying a local anesthetic to the mucosa in the back of each nostril to numb the nerves that cause the headache. The investigators hope that the SPGB will reduce the number of PDPH patients that require and EBP.

Conditions

Interventions

TypeNameDescription
DRUG0.5% bupivacaineThis group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
DRUGnormal salineThis group will receive 0.3 ml of normal saline per nare, applied with the Tx360®

Timeline

Start date
2015-06-29
Primary completion
2016-08-30
Completion
2016-08-30
First posted
2015-02-19
Last updated
2017-09-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02365909. Inclusion in this directory is not an endorsement.